RxDoctor Payments DataLook up a doctor →

Rishi Puri, MD

Interventional Cardiology · Cleveland, OHNPI 1821570128

Payments from drug & device makers

$544,169in general payments, 2019–2025

Across 438 payments — averaging $1242.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$337K
  • Abbott$177K
  • Centerline Biomedical Inc.$15K
  • Shockwave Medical, Inc$8K
  • Boston Scientific$3K
  • Ancora Heart, Inc.$2K
  • plus $2K from 9 others
$8,719in research payments, 2019–2025

Across 8 payments — averaging $1089.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$9K

What the payments were for

  • Consulting fees$126,67869%
  • Speaking & faculty fees$16,4699%
  • Travel & lodging$27,75615%
  • Food & beverage$13,6377%
  • Other$2820%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$544,169 in reported general payments places this provider in the 90th percentile of 256 interventional cardiology providers in Ohio.

See all interventional cardiology providers in Ohio

Medicare billing

Part B allowed, 2024
$163,857
Medicare patients
405
Services billed
851

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin101$134,012
EntrestoSacubitril/Valsartan75$96,196
EliquisApixaban80$80,924
FarxigaDapagliflozin Propanediol56$65,788
Repatha SureclickEvolocumab81$50,854
Repatha PushtronexEvolocumab49$35,668
BrilintaTicagrelor20$11,664
Prasugrel Hcl25$2,691
Ranolazine ErRanolazine23$2,441
Rosuvastatin Calcium150$2,360
Atorvastatin Calcium154$1,854
Ezetimibe78$1,759
Metoprolol Succinate88$1,189
ClopidogrelClopidogrel Bisulfate114$1,189
Isosorbide Mononitrate ErIsosorbide Mononitrate61$1,157

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →